[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1996

Failure of Topical Polymyxin B to Improve Mild Plaque Psoriasis

Author Affiliations

Department of Dermatology University of Michigan Medical Center 1910 Taubman Center Ann Arbor, MI 48109-0314

Arch Dermatol. 1996;132(2):231. doi:10.1001/archderm.1996.03890260135023
Abstract

Protein kinase C (PKC) is an enzyme involved in the regulation of cellular growth and differentiation. Hegemann et al1 tested various PKC inhibitors in an immortalized keratinocyte cell culture. They showed that the degree of inhibition of cell proliferation was proportional to the potency of PKC inhibition. The authors speculated that PKC inhibitors might be effective for treatment of psoriasis.

Hegemann et al showed that polymyxin B is a relatively potent inhibitor of PKC; however, unlike the other PKC inhibitors tested, polymyxin B caused little inhibition of cell proliferation in their culture system. Hegemann et al suspected that the polar polymer structure of polymyxin B prevented its penetration through keratinocyte cell membranes.

Polymyxin B is in common use in over-the-counter preparations with an excellent safety record. Despite its poor inhibition of cell proliferation in culture, we performed a double-blind, randomized, bilateral, vehicle-controlled study comparing the effectiveness of topical polymyxin

First Page Preview View Large
First page PDF preview
First page PDF preview
×